Proteolix Overview

  • Year Founded
  • 2003

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 32

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $851M

Proteolix General Information

Description

Operator of a biopharmaceutical company intends to discover, develop, and commercialize target protein degradation pathways for cancer and autoimmune diseases. The company offers to evaluate safety and efficacy in multiple myeloma and other malignancies and is also developing a pipeline of novel proteasome inhibitors, including an oral proteasome inhibitor and a selective immunoproteasome inhibitor, enabling doctors with a therapeutic that inhibits the cellular proteasome to treat certain hematologic cancers.

Contact Information

Website
www.proteolix.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 333 Allerton Avenue
  • South San Francisco, CA 94080
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Onyx Pharmaceuticals
Vertical(s)
HealthTech, Life Sciences, Oncology
Corporate Office
  • 333 Allerton Avenue
  • South San Francisco, CA 94080
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Proteolix Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Merger/Acquisition 12-Oct-2009 $851M Completed Clinical Trials - Phase 2
4. Later Stage VC Completed Clinical Trials - Phase 2
3. Later Stage VC (Series C) 27-Aug-2008 Completed Generating Revenue
2. Early Stage VC (Series B) 31-May-2006 $45M $63.3M Completed Startup
1. Early Stage VC (Series A) 29-Jul-2005 $18.3M $18.3M Completed Startup
To view Proteolix’s complete valuation and funding history, request access »

Proteolix Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Proteolix Former Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
Advanced Technology Ventures Venture Capital Minority
Delphi Ventures (California) Venture Capital Minority
Latterell Venture Partners Venture Capital Minority
Phase4 Partners Venture Capital Minority
Pivotal Capital Partners Growth/Expansion Minority
You’re viewing 5 of 9 investors. Get the full list »

Ready to get started?

Request a free trial

Proteolix FAQs

  • When was Proteolix founded?

    Proteolix was founded in 2003.

  • Where is Proteolix headquartered?

    Proteolix is headquartered in South San Francisco, CA.

  • What is the size of Proteolix?

    Proteolix has 32 total employees.

  • What industry is Proteolix in?

    Proteolix’s primary industry is Drug Discovery.

  • Is Proteolix a private or public company?

    Proteolix is a Private company.

  • What is the current valuation of Proteolix?

    The current valuation of Proteolix is .

  • What is Proteolix’s current revenue?

    The current revenue for Proteolix is .

  • How much funding has Proteolix raised over time?

    Proteolix has raised $142M.

  • Who are Proteolix’s investors?

    Advanced Technology Ventures, Delphi Ventures (California), Latterell Venture Partners, Phase4 Partners, and Pivotal Capital Partners are 5 of 9 investors who have invested in Proteolix.

  • When was Proteolix acquired?

    Proteolix was acquired on 12-Oct-2009.

  • Who acquired Proteolix?

    Proteolix was acquired by Onyx Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process